omicron covid-19 vaccine (vero cell), inactivated

VaccineexperimentalCOVID-19

Clinical trial activity

7 trials · 10 clinical orgs · 0 marketing orgs

Phase 1
3
Phase 2
4
Phase 3
3
Phase 4
0

Earliest trial started Mar 15, 2022 (NCT05203419)

Timeline

2020s

  1. Jan 1, 2022

    Earliest Phase 1 Sponsor(trial)

  2. Jan 1, 2022

    Earliest Phase 3 Sponsor(trial)

Indications

Mechanism of action

  • SARS-CoV-2Immunity, active

    SARS-CoV-2 immunity, active

Chemistry & pharmacology

Oral

No

Parenteral

No

Topical

No

Clinical trials

NCT IDPhaseStart dateSponsor(s)
NCT05272059Phase 1Feb 13, 2023Novartis
NCT05574985N/AAug 29, 2022Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd., Bengbu Medical College
NCT05381350Phase 3Jun 1, 2022Government of China, Sinovac Biotech Co., Ltd
NCT05382871Phase 3May 27, 2022Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, The University of Hong Kong, Wuhan Institute of Biological Products Co., Ltd
NCT05374954Phase 3May 10, 2022Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Government of China
NCT05365724Phase 1/Phase 2 (Phase 2)May 1, 2022Beijing Tiantan Bio Co., Ltd, China National Biotec Group Co., Ltd, Hangzhou Hospital of Traditional Chinese Medicine
NCT05203419Phase 1Mar 15, 2022Novartis
Showing 7 of 7 trials
Page 1 / 1

Organizations

Research & Development (10)

OrganizationOrg typeTrialsAs lead sponsorPhasesEarliest year
Beijing Tiantan Bio Co., LtdFor profit3022022
China National Biotec Group Co., LtdFor profit3322022
Government of ChinaGovernment2012022
NovartisFor profit2212022
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.For profit1112022
Bengbu Medical CollegeAcademic/Hospital1012022
Hangzhou Hospital of Traditional Chinese MedicineAcademic/Hospital1012022
Sinovac Biotech Co., LtdFor profit1112022
The University of Hong KongAcademic/Hospital1012022
Wuhan Institute of Biological Products Co., LtdGovernment1012022
10 organizations
Page 1 / 1